慢性肾脏病 中国就医指南

Chronic Kidney Disease (CKD) is a progressive, long-term condition characterized by gradual and irreversible loss of kidney function over months or years. Defined by the presence of kidney damage—evidenced by structural or functional abnormalities (e.g., albuminuria, abnormal imaging, or biopsy findings)—or reduced glomerular filtration rate (GFR) <60 mL/min/1.73m² for ≥3 months, CKD is staged from 1 (mild) to 5 (end-stage kidney disease, ESKD). Pathogenesis involves sustained injury to nephrons from hemodynamic stress, inflammation, fibrosis, and oxidative stress. Key drivers include dysregulated renin-angiotensin-aldosterone system (RAAS), podocyte injury, tubulointerstitial fibrosis, and maladaptive repair mechanisms. Common underlying causes are diabetes mellitus (accounting for ~40% of cases globally), hypertension, glomerulonephritis, polycystic kidney disease, and chronic urinary tract obstruction. Epidemiologically, CKD affects approximately 10–14% of the global adult population—over 800 million people—with prevalence rising sharply in aging societies and low- to middle-income countries. In China, national surveys estimate a prevalence of 10.8%, translating to more than 130 million affected adults; however, awareness remains low, with fewer than 12% of patients diagnosed early. Major modifiable risk factors include uncontrolled type 2 diabetes, systemic hypertension, obesity, smoking, prolonged NSAID use, and recurrent acute kidney injury. Non-modifiable risks include older age, family history, and certain ethnicities (e.g., Han Chinese with APOL1 risk variants remain under-studied but emerging evidence suggests heightened susceptibility). CKD profoundly impacts quality of life: fatigue, sleep disturbances, depression, cognitive impairment, sexual dysfunction, and dietary restrictions contribute to diminished physical functioning and social participation. As GFR declines, patients face escalating risks of cardiovascular events—the leading cause of death in CKD—and progression to dialysis or transplantation. Early detection via serum creatinine–based eGFR estimation and urine albumin-to-creatinine ratio (UACR) screening is critical for timely intervention. Without effective management, CKD imposes substantial socioeconomic burden—not only through direct medical costs but also lost productivity, caregiver strain, and premature mortality. Multidisciplinary care involving nephrologists, dietitians, pharmacists, and mental health professionals significantly improves outcomes and patient-reported well-being.

# 慢性肾脏病（CKD）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：CKD 1–3期，eGFR ≥30 mL/min/1.73m²，无严重并发症

• •基础管理：低蛋白饮食指导、血压/血糖控制、戒烟限盐

• •药物治疗（按档次）：

- 进阶档（SGLT2抑制剂+ERA+磷结合剂）：月均药费 1,200–2,800元 - 高端档（新型降蛋白尿药+靶向铁剂+维生素D类似物）：月均药费 2,500–4,500元

二、手术/介入治疗方案

适用人群：CKD 4–5期，eGFR <15 mL/min/1.73m²，或需建立血管通路/腹膜透析准备

• •动静脉内瘘成形术（AVF）：术前检查（超声+心电图+凝血+感染四项）1,000–1,500元；手术费+麻醉+住院（5–7天）12,000–18,000元
• •腹膜透析置管术：术前检查同上；手术+置管+术后护理（4–6天）15,000–22,000元
• •长期中心静脉导管置入（临时通路）：8,000–13,000元（含术前评估及住院）

三、晚期/复杂/并发症方案

• •难治性肾性贫血（ESA抵抗）：HIF-PHI类药（罗沙司他）月均2,000–3,500元；输血支持单次1,800–3,000元
• •继发性甲旁亢（iPTH >800 pg/mL）：拟钙剂（西那卡塞）月均1,500–2,600元；甲状旁腺切除术（PTX）全套28,000–42,000元
• •终末期CKD合并心衰/严重感染：多学科联合管理，月均综合治疗费（含CRRT、抗生素、监护）35,000–65,000元

四、方案快速选择指南

• •预算有限（<500元/月）：优选基础药物+生活方式干预+社区随访
• •中等预算（1,500–3,000元/月）：SGLT2抑制剂+规范透析通路准备+定期肾病专科随访
• •急重症/晚期患者：优先AVF/腹透置管+多学科会诊，医保报销后自付约30%–50%